Comparative Pharmacology
Head-to-head clinical analysis: HIPPURAN I 131 versus INDIUM IN 111 PENTETREOTIDE KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HIPPURAN I 131 versus INDIUM IN 111 PENTETREOTIDE KIT.
HIPPURAN I 131 vs INDIUM IN-111 PENTETREOTIDE KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HIPPURAN I 131 (iodohippurate sodium I-131) is a radiopharmaceutical that is actively transported by the renal tubules, allowing dynamic imaging of renal function. The I-131 isotope emits beta and gamma radiation, enabling scintigraphic visualization of renal perfusion and excretion.
Indium In-111 pentetreotide binds to somatostatin receptors, particularly subtypes 2 and 5, allowing scintigraphic localization of primary and metastatic neuroendocrine tumors bearing these receptors.
1 mCi (37 MBq) intravenously for adults; dose adjusted based on clinical indication and imaging protocol.
111 MBq (3 mCi) indium In-111 pentetreotide administered intravenously over 1 minute; single dose for planar and SPECT imaging.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in patients with normal renal function; prolonged in renal impairment, up to 20-40 hours in severe impairment.
Terminal half-life approximately 24 hours (range 22-26 hours), allowing imaging up to 24-48 hours post-injection
Renal: >95% excreted unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Renal: 80-90% unchanged within 24 hours; Fecal: 5-10%
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical